The FDA's new draft IVD Guidelines will need to be factored into how pharma clinical trial sponsors use IVDs in a clinical trial, study design, timeline for protocol development, IND submission, and study initiation.
Michele L. Buenafe
Advertisement
Articles by Michele L. Buenafe
Advertisement
Latest Updated Articles
- What Pharma Companies Need to Know About FDA's New Draft IVD Guidance
Published: February 12th 2018 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Thermo Fisher, Lundbeck Announce New OpenAI Partnerships Advancing AI in Drug Development
2
Using Global Patient Data to Design Smarter, More Inclusive Clinical Trials
3
ACT Brief: AI Expands Global Site Leadership as Ozempic Shows Potential to Reverse Biological Age
4
ACT Brief: AI Partnerships, Data-Driven Site Activation, and FDA Approval for Omvoh’s Single-Injection Regimen
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
